VYCO (Vycor Medical) Ending Cash Position : $0.16 Mil (As of Sep. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Vycor Medical Ending Cash Position?

Vycor Medical's Ending Cash Position for the quarter that ended in Sep. 2024 was $0.16 Mil.

Vycor Medical's quarterly Ending Cash Position increased from Mar. 2024 ($0.04 Mil) to Jun. 2024 ($0.12 Mil) and increased from Jun. 2024 ($0.12 Mil) to Sep. 2024 ($0.16 Mil).

Vycor Medical's annual Ending Cash Position declined from Dec. 2021 ($0.09 Mil) to Dec. 2022 ($0.04 Mil) but then increased from Dec. 2022 ($0.04 Mil) to Dec. 2023 ($0.06 Mil).

Vycor Medical Ending Cash Position Historical Data

The historical data trend for Vycor Medical's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vycor Medical Ending Cash Position Chart

Vycor Medical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

0.06

0.05

0.09

0.04

0.06

Vycor Medical Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Ending Cash Position	Get a 7-Day Free Trial															0.07	0.06	0.04	0.12	0.16

Vycor Medical Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Vycor Medical's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	0.037	+	0.02
	=	0.06

Vycor Medical's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	0.12	+	0.038
	=	0.16

Vycor Medical Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Vycor Medical's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Vycor Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vycor Medical Inc (OTCPK:VYCO) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

951 Broken Sound Boulevard, Suite 320, Boca Raton, FL, USA, 33487

Website

https://www.vycormedical.com

Vycor Medical Inc is engaged in designing, developing and marketing medical devices for use in neurosurgery in the United States. It has developed ViewSite Brain Access System, which helps to reduce brain tissue trauma that arises from excessive pressure at the edges of the blade. It also provides non-invasive rehabilitation therapies for patients having disorders resulting from neurological brain damage caused by a stroke. The company operates through two segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neurostimulation therapies and diagnostic devices for the treatment and screening of visual field loss. The majority of the revenue comes from the Vycor Medical segment in the United States.

Executives

David Cantor	director, officer: President	1 PORTMAN HOUSE HUE STREET, ST HELIER, JERSEY CHANNEL ISLANDS X0 00000
Adrian Liddell	director, officer: Chairman	ROSEMOUNT, LYNCOMBE VALE ROAD, BATH HI BA2 4LP
Peter C Zachariou	director, 10 percent owner, officer: Chief Executive Officer	C/O QUE MANAGEMENT INC, 180 VENICK 13RH FL, NEW YORK NY 10014
Lowell Rush	director	C/O DIRECT INSITE CORP., 500 EAST BROWARD BOULEVARD, SUITE 1550, FORT LAUDERDALE FL 33394
Oscar Bronsther	director	4 AUTUMNWOOD COURT, THE WOODLANDS TX 77380
Steven Girgenti	director	C/O HEALTHWORLD CORP, 100 AVENUE OF THE AMERICAS, NEW YORK NY 10013
Fountainhead Capital Management Ltd	10 percent owner	PORTMAN HOUSE HUE STREET, ST HELIER, JERSEY CHANNEL ISLANDS X0 JE45RP

Vycor Medical Headlines

From GuruFocus

Vycor Medical Reports Financial Results for the year ended December 31st, 2019

By Marketwired Marketwired • 03-27-2020

Vycor Value Could be Unlocked with These Major Partnerships

By Last Financier Last Financier • 12-05-2014

Treatment for blindness successful in largest ever study

By Marketwired Marketwired • 02-26-2020

New Study Shows Vision Rehab Treatment Effective for Stroke and Injury Related Blindness

By Marketwired Marketwired • 02-27-2020

Vycor Medical Reports Financial Results for the Year Ended December 31st, 2017

By ACCESSWIRE AccessWire • 04-12-2019

Vycor Medical Reports Financial Results for the Year Ended December 31st, 2018

By ACCESSWIRE AccessWire • 04-12-2019

Vycor Medical, Inc. Agrees New NovaVision Licensing Agreement

By Marketwired Marketwired • 06-30-2020